EQT Life Sciences, a part of Swedish private equity company EQT AB (STO: EQT), announced on Monday that it has exited Vivasure Medical Limited, an Ireland-based developer of percutaneous vessel closure technology, through a sale to US medical technology group Haemonetics Corporation (NYSE: HAE).
Vivasure develops the PerQseal Elite system, which uses a bioabsorbable patch to seal large arterial or venous access sites from within, providing a sutureless and fully absorbable solution for structural heart and endovascular procedures. In 2025, the company submitted a Premarket Approval application to the US Food and Drug Administration for PerQseal Elite and received CE Mark approval in Europe for arterial and venous use.
EQT Life Sciences, formerly LSP, first invested in Vivasure in 2016 via the LSP Health Economics Fund, leading its Series C round. The transaction includes an upfront cash payment of EUR100m and up to EUR85m in contingent consideration linked to sales growth and other milestones, and the LSP Health Economics Fund will receive a portion of the proceeds reflecting its minority shareholding.
Haemonetics Corporation said the acquisition expands its range of closure devices and strengthens its position in the large-bore closure market for structural heart and endovascular procedures.
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
Agilent acquires Proscia for USD240m
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
Pentixapharm advances preparationsfor Phase 3 PANDA study
StimLabs launches DermaForm collagen scaffold particulate device
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia